Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EnGeneIC, an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, has announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,772,013 to EnGeneIC for its patent application entitled, "Methods for Targeted in Vitro and in Vivo Drug Delivery to Mammalian Cells via Bacterially Derived Intact Minicells."
Subscribe to our email newsletter
The patent describes and claims a targeted drug delivery method that combines bacterial minicells and a "bispecific ligand" in a composition lacking undesirable contamination from parent bacterial cells and so-called membrane blebs. The patented method draws on important discoveries by EnGeneIC inventors, including their finding that a range of different cancer cells, although non-phagocytic, nevertheless internalize drug-packaged minicells when they are targeted to the cells by a suitable bispecific ligand.
The inventors also discovered that any one of a variety of structurally dissimilar chemotherapeutic drugs can be packaged effectively into intact minicells. The EnGeneIC methodology therefore opens the way to exploiting drug candidates that have been deemed too toxic for human application.
Jennifer MacDiarmid, Ph.D., joint-CEO of EnGeneIC, commented, "This patent marks a substantial advance in a new oncology paradigm founded on EnGeneIC’s proprietary EDV nanocell platform. The patented technology affords pinpoint accuracy in delivering a chemotherapeutic drug to targeted tumor cells, reducing drug-related toxicity without sacrificing therapeutic impact. Moreover, the stability of EDV nanocells, due to their bacterial nature, prevents ‘payload leakage’ until they are internalized by cancer cells. As such, EDV nanocells offer the opportunity to utilize highly cytotoxic chemotherapeutic agents that are normally limited due to harmful toxicity to healthy tissues."
Himanshu Brahmbhatt, Ph.D., joint-CEO of EnGeneIC, continued, "With this patent EnGeneIC continues to build a global IP estate that already includes granted claims, in the U.S. and elsewhere, to using EDV nanocells to deliver not only small molecule chemotherapeutic drugs but also siRNA, miRNA and shRNA, among other nucleic acid molecules. The EDV nanocell technology is truly unprecedented in that no other technology has been able to combine elements of highly targeted, cytotoxic chemotherapy and cancer immunotherapy into a single therapeutic."